Information for health professionals

Similar documents
Newborn Bloodspot Screening Information for parents

Newborn Bloodspot Screening Information for parents

For the Ongoing Management of Babies under 1 year old.

Information for health professionals

Slide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Slide 1: The information has been produced with thanks to the NHS Newborn Blood Spot Screening Programme.

Newborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017

Congenital Hypothyroidism Referral Guidelines for Newborn Bloodspot Screening Wales

Newborn Blood Spot Screening Service. Information for Users

Attachment 1. Newborn Screening Program Description

Green Amber Red Assurance Level

Screening Division of Public Health Wales NBSW Annual Statistical Report 2017/18

SUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure

Newborn Screening in Manitoba. Information for Health Care Providers

NATIONAL PROTOCOLS. Newborn Bloodspot Screening Programme. Release: Version 1.0. Date: Feb 2017

Health and Wellness for all Arizonans. azdhs.gov

No.7 Newborn Bloodspot Screening Programme

NEWBORN SCREENING PRENATAL CURRICULUM

NORTHERN IRELAND NEWBORN BLOODSPOT SCREENING PROGRAMME

Initial Clinical Referral Standards after Newborn Screening for Congenital Hypothyroidism

A Guide for Prenatal Educators

Newborn Screening in Washington State Saving lives with a simple blood spot

(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;

Annual Report Calendar Year 2015

Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test

Clinical Guideline MANAGEMENT OF INFANTS BORN TO MOTHERS WITH GRAVES DISEASE AND AT RISK OF THYROTOXICOSIS

UK Newborn Screening for X-ALD - progress from a lab perspective

Annual Report Calendar Year 2014

Newborn Screening: Blood Spot Disorders

Biochemical Genetics

NEWBORN METABOLIC SCREEN, MINNESOTA

Neonatal Thyrotoxicosis Management of babies born to mothers with a history of hyperthyroidism (Grave s Disease)

Sickle Cell Disorder Referral Guidelines for Newborn Bloodspot Screening Wales Screening for Sickle Cell Disorder in Wales started on 1 June 2013

Lothian Guidance for Diagnosis and Management of Thyroid Dysfunction in Pregnancy

Molecular blood spot performance monitoring

Congenital hypothyroidism and your child

POPULATION BASED NATIONAL SCREENING PROGRAMMES IN POWYS TEACHING HEALTH BOARD

Early Intervention: The Importance of Newborn Screening

A Practical Guide to Newborn Bloodspot Screening In Ireland

A randomised controlled trial of iodine supplementation in extreme preterm infants

Newborn Screening. Helping babies start life healthy. Minnesota Newborn Screening Program

Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy

WEST MIDLANDS NEWBORN SCREENING LABORATORY ANNUAL REPORT

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Manchester Newborn Screening Laboratory Annual Report

Esther Briganti. Fetal And Maternal Health Beyond the Womb: hot topics in endocrinology and pregnancy. Endocrinologist and Clinician Researcher

A Clinical Guideline for the Newborn Blood Spot Screening Test

HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up

The Controversy on Mild (Compensated) Congenital Hypothyroidism The Path We Took to Resolve the Dilemma in Washington Newborn Screening

Screening Newborns for Congenital Disorders

Newborn Screening: Focus on Treatment

For Your Baby s Health Department of Health

CYSTIC FIBROSIS. The condition:

Lothian Guidance for Diagnosis and Management of Thyroid Dysfunction in Pregnancy.

Positive Newborn Screens: What do you do next?

FACTORS INFLUENCING NEONATAL THYROID-STIMULATING HORMONE LEVEL IN NAKHON PATHOM PROVINCE, THAILAND

Newborn screening project at departments of genetics and endocrinology SGPGIMS, Lucknow

Newborn bloodspot results: predictive value of screen positive test for thalassaemia major

Newborn Screening: Train the Trainer PPT Questions

1 APRIL 2007 TO 31 MARCH

ENTERAL NUTRITION Identifying risk of patients for enteral feeding problems: Low risk: Moderate risk: High risk:

Most common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the. Inborn errors of metabolism (IEM)

Public Health Screening Programmes Annual Report 1 April 2013 to 31 March 2014

Neonatal Hypoglycemia

NEWBORN SCREENING in Massachusetts: Answers for you and your baby

Standard of Newborn Care in the Age of Birth Plans. Stephanie Deal, MD Tiffany McKee-Garrett, MD

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015

Neonatal Hypoglycaemia Guidelines

History of Screening for CF and CH in New Zealand. Dianne Webster Diane Casey Kathy Bendikson Richard MacKay Paul Hofman

The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot

SUMMARY THE RELEVANCE OF THE NEONATAL URINE SCREENING FOR INBORN ERRORS OF METABOLISM PERFORMED IN QUÉBEC. Introduction

Newborn Metabolic Screening Programme. Annual Report

A Practical Guide to. Newborn Bloodspot Screening. in Ireland

Map of Medicine National Library for Health

T H E B E T T E R H E A L T H N E W S

Annual Report to the Newborn Screening Ontario Advisory Council Calendar Year 2017

NEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School

Clinical Standards for GH Treatment in Childhood & Adolescence.

Newborn hearing screening - well baby protocol Paediatrics > Screening > Newborn hearing screening

Guideline scope Neonatal parenteral nutrition

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

Clinical guideline Published: 27 June 2012 nice.org.uk/guidance/cg143

Assessing Mothers Knowledge of the Wisconsin Newborn Screening Program. Sara Wolfgram UW Master of Public Health Symposium August 11, 2006

GUIDE TO NEWBORN SCREENING PROGRAMME

Screening Babies at risk of Congenital Hyperthyroidism GL354

OB Well Baby Nursery Admission (Term) [ ] For specialty focused order sets for your patient, refer to: General

Screening for Congenital Hypothyroidism in Newborns: A Literature Update for the U.S. Preventive Services Task Force

Wales Neonatal Network Guideline CARE OF THE BABY WHO HAS BEEN BORN TO AN HIV POSITIVE MOTHER

EACH page also notes the relevant appendix from which additional information is obtained for particular conditions.

Prediction of congenital hypothyroidism based on initial screening thyroidstimulating-hormone

Sending and Receiving Newborn Screening Results in Indiana: The HIE Perspective

Routinisation, choice and parental reflections on decisions to accept newborn bloodspot screening

Community Genetics. Hanan Hamamy Department of Genetic Medicine & Development Geneva University Hospital

Screening for hypothyroidism

A look across the border

344 Thyroid Disorders

Comprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M

Thyroid Disorders. January 2019

MCADD. MEDIUM CHAIN ACYL CoA DEHYDROGENASE DEFICIENCY. Dietary management guidelines for dietitians

Transcription:

Changes to the Newborn Bloodspot Screening Policy for Congenital Hypothyroidism (CHT) in Preterm Babies A UK policy change has been agreed that will mean changes to: which preterm babies require second CHT tests the timing of these second bloodspot samples. Preterm babies require a second test for CHT as the routine bloodspot test result can be incorrectly negative because of the baby s prematurity. Revised CHT Preterm Policy Implementation Date: 1 st April 2012 It has been agreed that the revised CHT Preterm Policy will be implemented across the UK on the 1 st April 2012. All babies born on or after 1 st April 2012, at less than 32 weeks gestation (less than or equal to 31 weeks+6 days) should be offered a second preterm CHT test at 28 days of age (counting day of birth as day 0) or on day of discharge home whichever is the sooner. Please refer to pathway on page 5 Newborn Bloodspot Screening - For all babies cared for in hospital specialist units. The consultant neonatologist or general paediatrician is professionally responsible for ensuring that the second CHT sample is offered, and that the sample is obtained whilst the baby is an in-patient in neonatal or paediatric services. If a baby is moved to another hospital, responsibility for taking the second CHT sample is transferred to the receiving hospital. To enable the Newborn Screening Laboratory to report a valid CHT result, it is essential that the gestational age at birth is recorded on the bloodspot card.

The new policy will significantly reduce the number of babies who require a second preterm CHT test. The process of ensuring the second samples are taken should be clearer because the babies will still be on the neonatal or paediatric units when the second sample is required, and therefore responsibility for taking the sample is more clearly defined. Background Screening for CHT aims to detect babies who do not produce adequate thyroxine from birth. Babies may not produce adequate thyroxine because their thyroid gland has not developed, or has failed to develop properly, or they cannot produce active thyroid hormone due to an inherited deficiency. If babies with CHT are not treated they can develop a serious and permanent physical and mental disability. Babies who are identified as having CHT are treated with thyroxine tablets. Screening for CHT is based on thyroid stimulating hormone (TSH) levels measured in the bloodspot sample taken 5-8 days after birth (counting day of birth as day 0). Ideally, this sample is taken on day 5. Babies whose screening results show raised TSH levels are referred promptly to an endocrinologist for specialist care. Preterm infants, especially those born between 23 and 27 weeks gestation, are more likely to have low TSH levels at the time of the first routine newborn bloodspot screening test. This may be due to a number of factors including immaturity of thyroid function, the effects of acute illness and/or the use of iodine containing compounds in imaging and surgery. It is these preterm infants who show a delayed rise in TSH levels after birth who are the target population for the preterm second CHT screening test. Current CHT Preterm Policy Currently, all babies (irrespective of gestational age) have a bloodspot sample collected at day 5 to 8 of life for newborn screening. The existing CHT preterm policy is that babies born before 36 weeks gestation should also have a second sample collected for CHT when they reach the equivalent of 36 weeks gestational age. Page 2 of 5

Drawbacks of this policy are that very premature infants might wait up to twelve weeks for a second CHT test. There is also concern that a percentage of babies have an unnecessary second test. An expert sub-group comprising representatives from the British Society of Paediatric Endocrinology (BSPED), the British Association of Perinatal Medicine (BAPM) and the UK Newborn Screening Laboratory Network (UKNSLN) reviewed the evidence and consulted on reviewing the policy. They concluded that the optimal gestational age threshold for second testing is 32 weeks gestation (i.e 31 weeks + 6 days). Questions and Answers about the revised CHT preterm policy Do babies born before 1 st April 2012 need a second CHT preterm bloodspot test at 36 weeks? Prior to 1 st April 2012, the existing policy of second testing when a preterm baby reaches the equivalent of 36 weeks gestational age remains. There will also be a transition period which applies to preterm babies born before April 2012 who will not have had their second sample prior to 1 st April 2012. The Newborn Screening Laboratory will send out reminders for the second CHT bloodspot tests depending on date of birth and gestation. What are the implications of this policy for neonatal unit staff? The revised CHT preterm policy applies to babies born under 32 weeks gestational age. These babies will be under the care of the in-patient neonatal or paediatric services when the second CHT sample is due at 28 days of age. If babies are discharged home prior to 28 days of age they should have the second CHT sample taken on the day of discharge, before they go home. The consultant neonatologist or general paediatrician is professionally responsible for ensuring that the second CHT sample is offered, and that the sample is obtained whilst the baby is an in-patient in neonatal or paediatric services. The bloodspot samples will continue to be taken Page 3 of 5

Information for health health professionals by appropriate healthcare professionals providing care on the neonatal or paediatric units. If a baby is moved to another hospital, responsibility for taking the second CHT sample is transferred to the receiving hospital. What are the implications of this policy for midwives? All second CHT preterm samples should be taken whilst the babies are in-patients in neonatal or paediatric services. It is therefore unlikely that midwives will be required to take these second samples. How many bloodspots need to be collected for the second preterm CHT sample? Two bloodspots (two circles filled and evenly saturated) are required on the screening card for the second preterm CHT sample. Does the policy change affect the routine newborn bloodspot screening test? The routine newborn bloodspot screening test is not affected by the change in preterm CHT second policy. Samples for newborn bloodspot screening should be taken, 5-8 days after birth (counting day of birth as day 0). Ideally the samples should be taken on day 5. All babies (irrespective of gestational age) are offered this screening. The conditions currently screened for in Wales are phenylketonuria (PKU), congenital hypothyroidism (CHT) and cystic fibrosis (CF). Two additional newborn bloodspot screening tests will be introduced this year. Screening for medium chain Acyl-CoA dehydrogenase deficiency (MCADD) is due to start in June 2012, and screening for sickle cell disorders will be introduced from December 2012. Further information will be sent out to health professionals prior to the introduction of these new screening tests. Information provided with thanks to the UK Newborn Blood Spot Screening Programme (www.newbornbloodspot.screening.nhs.uk/chtpretermpolicy) Page 4 of 5

Newborn Bloodspot Screening For all newborn babies in hospital specialist units 1 April 2012 Admission Days 0-4 (date of birth =day 0) Give information and gain consent Gestational age at birth must be recorded on the blood spot card for laboratory to report a valid CHT result Blood transfusion? Days 5-8 (Ideally day 5) Take routine sample (4 spots) The date of the most recent blood transfusion must be recorded on the blood spot card Days 5-8 (Ideally day 5) Take routine sample (4 spots) An interval of 72 hours is required between a blood transfusion and a routine sample for PKU, CHT, CF & MCADD* Routine sample must be taken by day 8 at the latest, and a further repeat sample taken 72 hours after the last transfusion Multiple blood transfusion? Less than 32 weeks gestation? Pathway complete unless further sample requested by lab CHT Repeat sample taken (2 spots) at 28 days of age or on day of discharge from hospital, whichever is sooner Page 5 of 5